In 20021year, the net profit of Hebang Bio soared 73 times to 3 billion yuan, and the high growth of agrochemical and photovoltaic sectors will continue.

Wang Zhonghong Stock Channel March 16 On

In 20021year, the net profit of Hebang Bio soared 73 times to 3 billion yuan, and the high growth of agrochemical and photovoltaic sectors will continue.

Wang Zhonghong Stock Channel March 16 On the evening of March 14, Sichuan Hebang Biotechnology Co., Ltd. (stock abbreviation: Hebang Bio, stock code: 603077), a leading agrochemical enterprise, disclosed the brilliant annual performance report of 20021. The report shows that Hebang Bio 202 1 achieved an operating income of 9.867 billion yuan, an increase of 87.56% year-on-year; The net profit of returning to the mother was 3.023 billion yuan, a year-on-year surge of 7284.28%.

The annual report shows that Hebang Bio has long adhered to the guiding ideology of "first-class technology, first-class product quality and first-class manufacturing cost", and with the help of capital market forces, it has gradually completed the basic layout in three major fields, namely, chemical industry, agriculture and photovoltaics, and formed four business segments, namely, combined alkali, iminodiacetic acid/glyphosate, methionine and photovoltaics. Hebang Bio said that in the above four sectors, the company is in the leading position in the world or in the sales region respectively, and the strong growth of 202 1 performance is mainly due to the booming production and sales of the main products in the sector business.

In addition, Hebang Bio also announced that it plans to spin off and list its subsidiary Sichuan Wu Jun Optical Energy Technology Co., Ltd. (hereinafter referred to as "Wu Jun Optical Energy") and list it on the main board of Shanghai Stock Exchange. Hebang Bio said that through this spin-off, listed companies will further focus their business, which is beneficial to the business development of Wu Jun Solar in the field of green energy.

With the layout of the photovoltaic sector in the early stage entering the harvest period, the existing agrochemical business is still in a high boom sector. Analysts predict that the performance trend of Hebang Bio will still be on the rise in the future due to favorable factors such as market demand and policy support.

Off the charts achieved a net profit of 3 billion yuan for the whole year.

After the performance data of the semi-annual report and the third quarterly report of 20021continued to soar, the market had psychological expectations for the performance of Hebang Bio in 20021year. According to the data of the annual report, Hebang Bio 202 1 achieved an operating income of 9.867 billion yuan, an increase of 87.56% year-on-year; Realized a net profit of 3.023 billion yuan, a year-on-year surge of 7284.28%; Deducting non-net profit was RMB 3.0./kloc-0.0/0.40 billion, a year-on-year surge of 690.63%. At the same time, the company plans to distribute a cash dividend of 0. 15 yuan (including tax) for every 10 share based on the number of shares to be distributed on the base date when the profit distribution plan for 20021year is implemented.

On the whole, during the reporting period, Hebang Bio showed steady growth and super management resilience. Following the net profit of 2.009 billion yuan in the first three quarters of 20021,its annual performance is out of the chart again, and its investment value in the capital market is further revealed.

The company said that this substantial increase in performance benefited from the booming production and sales of iminodiacetic acid, glyphosate, glass, sodium carbonate, ammonium chloride and other major products. The annual report shows that during the reporting period, the prices and sales of the company's main products have increased. In addition, the company continuously improved management efficiency and staff quality, ensured the company's high-quality operation, and its operating income increased substantially.

According to the annual report, during the reporting period, the company continuously improved the capacity utilization rate and cost control level of PMIDA, glyphosate, methionine, soda ash production and photovoltaic glass devices through independent technological innovation, process innovation and introduction of advanced technology, which created technical conditions for the company to obtain good profit space.

The new product methionine reaches the production standard, and the future growth space appears.

In May of 2002 1 year, Hebang Bio once said on the investor exchange platform: "From June to April of1year, the company sold thousands of tons of methionine." The annual report also revealed that the Hebang Bio-methionine Project was officially put into operation at the end of 20021,which indicated that the company's technological operation ability of high-tech, large-scale complex chemical plants in the chemical field was improved again, and the operation site of the company's methionine project was completely colorless and tasteless, which marked the company's green development level to a higher level.

Everbright Securities pointed out in a research report in June 200211that the market price of methionine in China continued to decline after experiencing a sharp rise and fall of 20 14-20 15. At present, the price is basically at the bottom and there is a broad room for growth.

TF Securities research report shows that the methionine market is stable. According to foreign media reports, due to the rise of natural gas and other raw materials, CJ methionine international quotation has increased by 10% from 1 in October 2022. According to customs statistics, the domestic methionine import in February and February of 2002 was 2 1 1,885 tons, down 3.6% year-on-year. The chain increased by 7237 tons, an increase of 49%.

After the production line of Hobon Bio-methionine is put into production, it will become the second enterprise in China to realize mass production of liquid methionine. "The company plans to continue to develop for one to two years on the basis of stable operation and process optimization of methionine project, with the goal of becoming the world's leading liquid methionine manufacturer." Hebang Bio said earlier.

The subsidiary intends to spin off new materials for listing, and the market outlook can be expected.

Hebang Bio also disclosed the Pre-plan for the Listing of Sichuan Wu Jun Solar Energy Co., Ltd., a subsidiary, on the Main Board of the Shanghai Stock Exchange. The plan shows that the company intends to spin off its holding subsidiary, Wu Jun Solar, to the main board of Shanghai Stock Exchange for listing. After the spin-off, Hebang Bio will still hold the controlling stake in Wu Jun Solar.

According to the announcement, the main business of Wu Jun Solar in recent three years is to produce and sell high-quality primary glass, Low-E coated glass and product glass. From 20 19 to 202 1, Wu Jun Solar achieved revenue of 9110000000 yuan, 986 million yuan and13.93 million yuan respectively; The net profit of returning to the mother was 65.438+0.34 billion yuan, 24.65438+0 million yuan and 492 million yuan respectively.

Hebang Bio said that through this spin-off, the company will further focus on its business, highlight its main business, focus on the development of traditional chemical industry and agriculture, and become better and stronger. At the same time, the independent listing of Wu Jun Solar, a holding subsidiary, as the main business entity of glass products and photovoltaic business, is conducive to enhancing capital strength and investment and financing capabilities, optimizing corporate governance structure, seizing the market opportunity of photovoltaic industry development, enhancing business competitiveness, strengthening the layout of the company in the photovoltaic field, promoting the all-round development of the company's business, improving the overall asset quality and enhancing the overall profitability of the company.

At present, Wu Jun Solar has been counseling and filing in Shanghai Stock Exchange, and will continue to improve the performance of Bangbio with the advantage of industrial chain after listing in the future.

In terms of new materials business, the preliminary layout project of Hebang Bio is progressing smoothly. The annual report shows that the project of Wu Jun with an annual output of 8GW photovoltaic packaging materials and products is implemented as planned; Fuxing technology's annual output of 10GWN+ ultra-efficient monocrystalline silicon solar silicon wafer project was implemented as planned; The project of photovoltaic packaging materials and products in Chongqing started at the beginning of 2002 1, and will gradually enter trial production and put into production from March 27th, 2022 to June 20th, 20231.

In addition to the above projects, Hebang Bio has also made frequent capital moves in the field of new materials.

202110/9, Hebang Bio announced that its subsidiary Wu intends to jointly establish Anhui Fuxing Crystal Technology Co., Ltd. with Tongxingxue, Hainan Renai Cultural Center and Tianjin New Energy Partnership * *, with a total investment of 3 billion yuan and an initial registered capital of 455 million yuan. The production mode of this project is mainly to use high-purity solar-grade silicon materials to produce silicon wafers through crystal growth, slicing and other manufacturing processes. Wu Jun Solar, which is to be split and listed, holds 58.33% equity of Anhui Fuxing New Energy Technology Co., Ltd. ..

According to public information, in addition to capital contribution, investor Tong Xingxue will also provide full-service for Fuxing Technology, provide advanced technical support for the project and set up a company operation team. Tong Xingxue has more than 20 years' experience in photovoltaic industry in global solar. He has held senior management positions in many companies at home and abroad, and applied for more than 200 patents, which has filled the gaps in domestic and foreign products and technologies in many links of the photovoltaic industry chain, and is undoubtedly of great help to the development of cooperative projects.

The announcement issued by Hebang Bio also shows that after the project is put into production, it is estimated that the annual sales revenue will be 6.5 billion yuan and the total annual profit will be 1 1.7 1 billion yuan. After the project is implemented, it will further optimize the company's industrial layout and enhance its competitiveness, which is in line with the company's long-term development plan and the interests of all shareholders and is conducive to the company's sustainable development.

It is worth mentioning that on March 10, Hebang Bio also disclosed the main operating data of June1-February 2022. According to preliminary accounting, during the period of 1-2 in 2022, Hebang Bio realized a total operating income of about1800 million yuan, an increase of about100% year-on-year; The net profit attributable to shareholders of listed companies was about 650 million yuan, a year-on-year increase of about 500%. Faced with a good performance start, analysts of Open Source Securities expressed optimism that Hebang Bio will achieve a steady improvement in its performance in 2022 by virtue of its global leading position in Southwest soda giant and phosphonomethyl phosphate. It is further considered that with the orderly development of photovoltaic glass, monocrystalline silicon wafer and phosphate rock, the upstream and downstream product chains of the company are further extended and the product pattern is further enriched, and the development prospect of Hebang Bio can be expected.